KOB 03

Drug Profile

KOB 03

Alternative Names: KOB-03

Latest Information Update: 16 Dec 2015

Price : $50

At a glance

  • Originator Dongguk University
  • Developer Dong Wha Pharmaceutical; Dongguk University
  • Class Anti-inflammatories; Antiallergics; Herbal medicines
  • Mechanism of Action Cytokine inhibitors; Extracellular signal-regulated MAP kinase inhibitors; Gene expression inhibitors; Histamine release inhibitors; Immunomodulators; Interleukin 1 beta inhibitors; Interleukin 6 inhibitors; Interleukin 8 inhibitors; Mast cell modulators; NF-kappa B inhibitors; P38 mitogen-activated protein kinase inhibitors; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Allergic rhinitis

Most Recent Events

  • 16 Dec 2015 Phase-II development for Allergic rhinitis is ongoing in South Korea
  • 15 Nov 2013 Dongguk University and Dong Wha Pharmaceuticals enter into technology transfer agreement for the development of KOB 03
  • 15 Nov 2013 Phase-II clinical trials in Allergic rhinitis in South Korea (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top